Milestone Revolutionizes Urban Infrastructure and Traffic Systems in Europe With NVIDIA and Project Hafnia, Starting With Genoa
11.6.2025 13:10:00 CEST | Business Wire | Press Release
After launching in the USA, Milestone’s Project Hafnia is now engaged in Europe with the city of Genoa, Italy. The aim is to develop AI-driven solutions to enhance traffic management systems and create smarter cities with high-quality, regulation compliant video data trained with NVIDIA NeMo Curator on NVIDIA DGX Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611227692/en/
Genoa, Italy.
Milestone is one of the early adopters of the newly announced NVIDIA Omniverse Blueprint for Smart City AI, a reference framework for optimizing city operations with digital twins and AI agents. Milestone is also expanding its data platform with NVIDIA Cosmos to generate synthetic video data from real world inputs. Leveraging both real and synthetic data, Milestone will build and train vision language models (VLMs) responsibly. European cloud provider Nebius will provide the required GPU compute to train the models.
AI opens up new horizons for smarter, more efficient cities with Project Hafnia’s data platform - from intelligent traffic and transportation management to better safety and security for people and property.
VLMs learn to map the relationships between text data and visual data such as images or videos, allowing these AI-models to generate summaries and insights from visual inputs. Milestone Systems is working with NVIDIA to empower European cities like Genoa to build and fine-tune computer vision and AI applications on a foundation of fully compliant and ethically sourced data. The project is rooted in regulatory integrity, data diversity, and AI relevance, aligning with the EU’s legal frameworks, including GDPR and the AI Act. This ensures both transparency and fairness in the development of AI technologies.
“I’m proud that with Project Hafnia we are introducing the world’s first platform to meet the EU’s regulatory standards, powered by NVIDIA technology. With Nebius as our European cloud provider, we can now enable compliant, high-quality video data for training vision AI models — fully anchored in Europe. This marks an important step forward in supporting the EU’s commitment to transparency, fairness, and regulatory oversight in AI and technology — the foundation for responsible AI innovation,” says Thomas Jensen, CEO of Milestone.
Milestone’s Project Hafnia provides the missing link for developing video-centric AI innovation with a fully compliant and ethically sourced data library for fine tuning classical video analytics models and VLMs.
The VLM’s accuracy and performance optimizations are tuned for running on NVIDIA GPUs and in NVIDIA AI Blueprint for video search and summarization (VSS).
First service offering trained on transportation data from Genoa
Project Hafnia now offers a fully European Visual Language Model for transportation management. The VLM is powered by NVIDIA and trained on a large volume of responsibly sourced and compliant transportation data from Genoa, Italy.
"AI is achieving extraordinary results, unthinkable until recently, and the research in the area is in constant development. We enthusiastically joined forces with Project Hafnia to allow developers to access fundamental video data for training new Vision AI models. This data-driven approach is a key principle in the Three-Year Plan for Information Technology, aiming to promote digital transformation in Italy and particularly within the Italian Public Administration,” says Andrea Sinisi, Information Systems Officer, City of Genoa.
While the focus of these collaborations is initially on video data, the framework is designed to scale across multiple domains and modalities, enabling future expansion and adaptation improving the value of the data. Both the compliant dataset and the fine-tuned VLM will be made available to the cities using Project Hafnia through a controlled access license model, facilitating Europe’s AI ambitions without compromising ethical standards.
Nebius to serve as European cloud solution
NVIDIA cloud provider, Nebius, will serve as the EU-based cloud solution for Project Hafnia’s collaboration with Genoa. Choosing Nebius as a sovereign cloud provider ensures full compliance with European data protection regulations, supports digital sovereignty objectives and guarantees that sensitive public-sector data remains securely within EU jurisdiction.
“Project Hafnia is exactly the kind of real-world, AI-at-scale challenge Nebius was built for,” says Roman Chernin, Chief Business Officer of Nebius.“Supporting AI development today requires infrastructure engineered for high-throughput, high-resilience workloads, with precise control over where data lives and how it’s handled. From our EU-based data centers to our deep integration with NVIDIA’s AI stack, we’ve built a platform that meets the highest standards for performance, privacy and transparency.”
ABOUT PROJECT HAFNIA
When training an AI model, high-quality data is essential. Just like a person learns by absorbing knowledge, AI models require vast amounts of structured data to develop reliable insights. But where does this data come from?
Enter Project Hafnia.
Project Hafnia acts as the trusted librarian of AI video data, carefully curating, tagging, and delivering ethically sourced, regulation-ready video data for AI model training. By leveraging Project Hafnia, AI learns from high-quality, verified video data, ensuring not only precision and compliance but also the protection of citizen privacy.
The vast network of end-customers, distributors and tech-partners enables Milestone to organize the world’s Video Data Eco-system with Project Hafnia and drive AI development even further.
With Project Hafnia, companies can confidently build and deploy AI models without compromising on compliance or quality.
About Milestone Systems
Milestone Systems is a world leader in data-driven video technology used in industries as diverse as manufacturing, airports, law enforcement, retail, and traffic management. We provide a clear picture of how to create a safer, better and more prosperous world. Our XProtect video management software, BriefCam AI-powered analytics, and Arcules cloud VSaaS help our customers learn from the past, understand the present, and predict the future. Founded in 1998 and headquartered in Copenhagen, Milestone employs more than 1,500 people worldwide and has been an independent company in the Canon Group since2014. For more information visit: www.milestonesys.com. For news and other press releases, visit our Newsroom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611227692/en/
Contacts
Lisbeth Nedergaard
Vice President, Communications
lin@milestone.dk
Tel: +45 4176 0272
Sophie Cederstrøm
Senior PR Advisor
sce@milestone.dk
Tel: +45 50 84 29 55
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom